Industry watchers expected a show at Thursday's congressional drug price hearing, and the event did not disappoint. Members of Congress slammed Valeant and Turing Pharmaceuticals for dramatic prices increases, and also took shots at former Turing CEO Martin Shkreli, who remained close-lipped throughout the hearing.
Pharma eyes are watching Capitol Hill on Thursday, where drug-price hikes will go on trial in a much-publicized congressional committee hearing. Valeant interim CEO Howard Schiller and ex-Turing Pharmaceuticals chief Martin Shkreli will get a grilling, though Schiller is the only one expected to answer any questions.
Gilead Sciences is scheduling a meeting with Massachusetts Attorney General Maura Healey after last week's threat of legal action against the company. And though some legal experts doubt Healey's standing in a court fight over Gilead's high prices on hep C drugs, the AG's office apparently sees some backing for the idea.
Don't expect Roche's cancer drugs to get caught in the crosshairs as payers ratchet up the pressure on drug prices, the company's head of pharmaceuticals, Daniel O'Day, told Reuters.
Remember the days when drugmakers could raise prices without sparking political pushback? Novartis CEO Joe Jimenez does--and he says they're not coming back.
Democratic presidential candidates Hillary Clinton and Bernie Sanders have already taken aim at pharma, talking up plans to give Medicare power to negotiate drug prices. Now, a less likely candidate has backed the idea: Donald Trump.
Pharma bro Martin Shkreli is requesting a hall pass to get out of testifying at a congressional hearing on drug pricing next week after receiving a subpoena ordering him to appear. But principals leading the price-fighting crusade including ringleader Rep. Elijah Cummings (D-MD) aren't letting Shkreli off the hook that easily.
Vocal pricing critic Rep. Elijah Cummings (D-MD) has his chance to put some pharma execs in the hot seat. Former Turing Pharmaceuticals CEO Martin Shkreli, who kicked off the latest brouhaha with an unapologetic 5,000% price increase, and Valeant Pharmaceuticals interim CEO Howard Schiller are expected next week at a congressional hearing on drug prices.
One country is ahead of the curve in striking pay-for-performance deals on cancer drugs--and, more importantly, collecting the cash when treatments don't hit their goals.
Less than a week after lawmakers asked the National Institutes of Health (NIH) and the U.S. Department of Health and Human Services (HHS) to take "extraordinary" action against rising drug prices, the agencies are getting a similar request from a nonprofit and cancer patient group. The latest target? Astellas' prostate cancer drug, Xtandi.